Search

everythinglearnresearchcommunity

for

Search:↓

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Prostate cancer risk is not linked to blood testosterone levels.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Men, particularly those with hair loss, are more likely to get the virus, and those with prostate cancer may have milder symptoms. Testosterone's role in the disease is unclear, and the virus doesn't seem to harm male fertility. Women with PCOS might be at higher risk. More research is needed.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

Excessive hair growth in women can be harmless or signal serious health issues, and treatment often includes medication and hair removal, with noticeable results after 3-6 months.

AGA affects many, progresses differently, and early treatment is crucial.

Human skin makes sexual hormones that affect hair growth, skin health, and healing; too much can cause acne and hair loss, while treatments can manage these conditions.

Hair loss in Androgenetic Alopecia is caused by genetics, aging, and lifestyle, leading to hair follicle shrinkage and related health risks.

New treatments for PCOS focus on managing symptoms and improving fertility.

Removing both ovaries may better treat increased male hormone levels and related symptoms in postmenopausal women when hormone therapy doesn't work.

Blood tests can detect ovarian Leydig cell tumors when scans don't, and surgery can confirm and treat these tumors.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Finasteride may improve prostate cancer treatment outcomes.

Certain Dibenzo derivatives may help treat prostate cancer.

Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Runx1 controls fat-related genes important for normal and cancer cell growth, affecting skin and hair cell behavior.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

High androgen levels can cause excessive hair growth and may indicate serious health issues, including heart disease and fertility problems.

Oral cyclosporin doesn't stop hair loss.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.

The 2003 consensus updated PCOS diagnosis criteria and linked PCOS to higher risks of diabetes and heart problems, recommending lifestyle changes to lower these risks.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

AGA progression involves increased lipid synthesis, electron transport, and hair follicle miniaturization.